ES2115571T3 - Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. - Google Patents
Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas.Info
- Publication number
- ES2115571T3 ES2115571T3 ES96917917T ES96917917T ES2115571T3 ES 2115571 T3 ES2115571 T3 ES 2115571T3 ES 96917917 T ES96917917 T ES 96917917T ES 96917917 T ES96917917 T ES 96917917T ES 2115571 T3 ES2115571 T3 ES 2115571T3
- Authority
- ES
- Spain
- Prior art keywords
- pps
- chronic progressive
- polisulfate
- pentosana
- scars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 230000000750 progressive effect Effects 0.000 title abstract 2
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 208000032544 Cicatrix Diseases 0.000 title 1
- 231100000241 scar Toxicity 0.000 title 1
- 230000037387 scars Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- JCSJTDYCNQHPRJ-MMDFAQQLSA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-beta-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)OC2)O)OC1 JCSJTDYCNQHPRJ-MMDFAQQLSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
LA INVENCION SE REFIERE A UN METODO PARA EL TRATAMIENTO DE UN PACIENTE MAMIFERO QUE SUFRE UNA ENFERMEDAD VASCULAR PROGRESIVA CRONICA (CPVD) CARACTERIZADA POR CICATRIZACION Y/O FIBROSIS CON EL FIN DE DETENER EL PROGRESO DE LA ENFERMEDAD Y RESOLVER LAS LESIONES DE CICATRIZACION O FIBROTICAS YA FORMADAS. EL METODO CONSISTE EN ADMINISTRAR AL PACIENTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UNA CANTIDAD EFICAZ DE POLISULFATO DE PENTOSANO (PPS) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. SE PREFIERE LA VIA ORAL DE ADMINISTRACION, CON DOSIS DIARIAS TOTALES DE PPS O DE SAL DE PPS DE ENTRE APROXIMADAMENTE 50 Y 1200 MG POR DIA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/478,347 US5643892A (en) | 1995-06-07 | 1995-06-07 | Method of treating chronic progressive vascular diseases |
PCT/US1996/008367 WO1996040158A1 (en) | 1995-06-07 | 1996-06-03 | Method of treating chronic progressive vascular diseases |
BR9704114-9A BR9704114A (pt) | 1995-06-07 | 1997-07-28 | Processo de tratamento de doenças vasculares progressivas crÈnicas |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2115571T1 ES2115571T1 (es) | 1998-07-01 |
ES2115571T3 true ES2115571T3 (es) | 2003-09-01 |
Family
ID=25664870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96917917T Expired - Lifetime ES2115571T3 (es) | 1995-06-07 | 1996-06-03 | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. |
Country Status (14)
Country | Link |
---|---|
US (1) | US5643892A (es) |
EP (1) | EP0809505B1 (es) |
AU (1) | AU699012B2 (es) |
BR (1) | BR9704114A (es) |
CA (1) | CA2210351C (es) |
DE (1) | DE809505T1 (es) |
ES (1) | ES2115571T3 (es) |
HU (1) | HUP9802431A3 (es) |
IL (1) | IL121217A (es) |
NO (1) | NO313686B1 (es) |
NZ (1) | NZ309991A (es) |
TW (1) | TW434018B (es) |
WO (1) | WO1996040158A1 (es) |
ZA (1) | ZA964247B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010005720A1 (en) * | 1995-06-07 | 2001-06-28 | U.S.A. As Represented By The Secretary Department Of Health And Human Services | Method of treating chronic progressive vascular scarring diseases |
US6255295B1 (en) | 1996-12-23 | 2001-07-03 | Nutramax Laboratories, Inc. | Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue |
UA65587C2 (en) | 1997-10-09 | 2004-04-15 | Baker Norton Pharma | Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus |
DE19747195A1 (de) * | 1997-10-24 | 1999-04-29 | Knoll Ag | Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten |
US20020010140A1 (en) | 2000-01-19 | 2002-01-24 | Striker Gary E. | Use of pentosan polysulfate to treat certain conditions of the prostate |
US20080214480A1 (en) * | 2005-07-22 | 2008-09-04 | Trf Pharma, Inc. | Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae |
NZ571537A (en) * | 2006-04-03 | 2012-06-29 | Nutramax Lab Inc | Stabilized pentosan polysulfate (PPS) formulations and methods of analayzing them |
JP5604417B2 (ja) | 2009-03-11 | 2014-10-08 | ゼライス株式会社 | アテローム性動脈硬化症の進行抑制薬・予防薬・血中コレステロール低下薬・機能性食品・特定保健用食品 |
US8871741B2 (en) * | 2010-01-15 | 2014-10-28 | Icahn School Of Medicine At Mount Sinai | Inhibition of TNF-α induced activation of NFKB by pentosan polysulfate |
JP6175431B2 (ja) | 2011-06-20 | 2017-08-02 | アイカーン スクール オブ メディシン アット マウント サイナイ | ムコ多糖症およびその他のリソソーム障害に対する抗tnf療法 |
US20130273096A1 (en) * | 2011-10-05 | 2013-10-17 | Bruce A. Daniels | Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients |
JP6935960B2 (ja) | 2018-08-20 | 2021-09-15 | 株式会社レクメド | 新規ポリ硫酸ペントサンナトリウム製剤 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820693A (en) * | 1986-05-22 | 1989-04-11 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
US4966890A (en) * | 1986-04-04 | 1990-10-30 | Angiogenics, Ltd. | Method and composition for arresting angiogenesis and capillary, cell or membrane leakage |
DE3725554A1 (de) * | 1987-08-01 | 1989-02-09 | Hoechst Ag | Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung |
US5032679A (en) * | 1988-12-15 | 1991-07-16 | Glycomed, Inc. | Heparin fragments as inhibitors of smooth muscle cell proliferation |
EP0466315A3 (en) * | 1990-05-30 | 1992-07-01 | Larrian Gillespie | Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation |
US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
-
1995
- 1995-06-07 US US08/478,347 patent/US5643892A/en not_active Expired - Fee Related
-
1996
- 1996-05-27 ZA ZA964247A patent/ZA964247B/xx unknown
- 1996-06-03 HU HU9802431A patent/HUP9802431A3/hu unknown
- 1996-06-03 DE DE0809505T patent/DE809505T1/de active Pending
- 1996-06-03 AU AU60300/96A patent/AU699012B2/en not_active Ceased
- 1996-06-03 WO PCT/US1996/008367 patent/WO1996040158A1/en active IP Right Grant
- 1996-06-03 NZ NZ309991A patent/NZ309991A/en unknown
- 1996-06-03 CA CA002210351A patent/CA2210351C/en not_active Expired - Fee Related
- 1996-06-03 EP EP96917917A patent/EP0809505B1/en not_active Expired - Lifetime
- 1996-06-03 ES ES96917917T patent/ES2115571T3/es not_active Expired - Lifetime
- 1996-06-03 IL IL12121796A patent/IL121217A/xx not_active IP Right Cessation
- 1996-08-03 TW TW085109390A patent/TW434018B/zh not_active IP Right Cessation
-
1997
- 1997-07-02 NO NO19973081A patent/NO313686B1/no unknown
- 1997-07-28 BR BR9704114-9A patent/BR9704114A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP9802431A3 (en) | 2001-06-28 |
BR9704114A (pt) | 2000-06-06 |
DE809505T1 (de) | 1998-05-28 |
US5643892A (en) | 1997-07-01 |
ES2115571T1 (es) | 1998-07-01 |
CA2210351A1 (en) | 1996-12-19 |
IL121217A0 (en) | 1999-10-28 |
AU6030096A (en) | 1996-12-30 |
CA2210351C (en) | 2003-09-23 |
NZ309991A (en) | 2001-03-30 |
NO973081L (no) | 1997-08-27 |
AU699012B2 (en) | 1998-11-19 |
IL121217A (en) | 2000-09-28 |
TW434018B (en) | 2001-05-16 |
NO313686B1 (no) | 2002-11-18 |
EP0809505B1 (en) | 2003-04-02 |
ZA964247B (en) | 1996-12-04 |
EP0809505A1 (en) | 1997-12-03 |
HUP9802431A2 (hu) | 1999-02-01 |
NO973081D0 (no) | 1997-07-02 |
WO1996040158A1 (en) | 1996-12-19 |
EP0809505A4 (en) | 1998-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2186737T3 (es) | Composiciones de oxicodona de liberacion controlada. | |
ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
ES2052717T3 (es) | Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson. | |
ES2160693T3 (es) | Formulacion estable de 10-hidroxi-7-etil-camptotecina en la forma lactona. | |
ES2170069T3 (es) | 1-alfa-hidroxiprevitamina d para administracion oral. | |
RU94046316A (ru) | Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза | |
ES2093735T3 (es) | Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. | |
ES2084579T3 (es) | Uso de buspirona en la preparacion de una composicion farmaceutica para el tratamiento del abuso del alcohol. | |
ES2115571T3 (es) | Uso de polisulfato de pentosana para la resolucion de cicatrices en enfermedades vasculares progresivas cronicas. | |
ES2153906T3 (es) | Uso de incienso para el tratamiento de la enfermedad de alzheimer. | |
GB2285219A (en) | Use of norastemizole for the treatment of allergic disorders | |
AR036312A1 (es) | Composicion farmaceutica | |
MX9205568A (es) | Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida. | |
IT1244636B (it) | Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento. | |
ES2119748T3 (es) | Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua. | |
CO4230093A1 (es) | Derivados del indol y sus usos medicos | |
MY124465A (en) | Reduction of infarct volume using citicoline | |
AR087240A2 (es) | Composiciones farmaceuticas que tienen epinastina y pseudoefedrina | |
KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
AR008559A1 (es) | Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo | |
AR006202A1 (es) | Usos de antagonista ige para preparar un medicamento util para el tratamiento de las enfermedades alergicas y composiciones que los contiene | |
KR890012942A (ko) | 5-치환된 오르니틴 유도체 | |
KR970005283A (ko) | 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도 | |
BR9509433A (pt) | Uso de (r-(z))-a-(metaxoiimino)-a-(1-azabiciclo-(2,2,2)oct-3-il)acetonitrila ou um sal farmaceuticamente aceitável da mesma processo para aperfeiçoar o processamento de uma proteina precursora de amilóide ao longo de um percurso não amiloidogênio processo para tratamento ou profilaxia do mal de alzheimer composição farmacêutica e uso processo ou composição | |
AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa |